Table 1.
Baseline characteristics, overall and by SPEAR status and treatment type
| All patients | SPEAR patients | Non-SPEAR patients | SPEAR versus non-SPEAR | ||||
|---|---|---|---|---|---|---|---|
| ABA | Comparator | ABA versus comparator | ABA | Comparator | |||
| N = 2073 | n = 819 | n = 581 | p value | n = 341 | n = 332 | p value | |
| Trial, n (%) | |||||||
| AGREE | 492 (23.73) | 177 (21.61) | 155 (26.68) | < 0.001 | 68 (19.94) | 92 (27.71) | < 0.001 |
| AMPLE | 508 (24.51) | 62 (7.57) | 69 (11.88) | 189 (55.43) | 188 (56.63) | ||
| AVERT | 339 (16.35) | 165 (20.15) | 83 (14.29) | 60 (17.60) | 31 (9.34) | ||
| AVERT-2 | 734 (35.41) | 415 (50.67) | 274 (47.16) | 24 (7.04) | 21 (6.33) | ||
| Demographics | |||||||
| Age (years) | 49.26 ± 12.86 | 48.49 ± 12.53 | 48.95 ± 13.47 | 0.51 | 49.87 ± 12.57 | 51.08 ± 12.74 | < 0.01 |
| Female, n (%) | 1,645 (79.35) | 630 (76.92) | 453 (77.97) | 0.69 | 282 (82.70) | 280 (84.34) | < 0.01 |
| Race, n (%) | 0.53 | < 0.001 | |||||
| Asian | 206 (9.94) | 106 (12.94) | 71 (12.22) | 17 (4.99) | 12 (3.61) | ||
| Black | 118 (5.69) | 38 (4.64) | 34 (5.85) | 27 (7.92) | 19 (5.72) | ||
| Other | 145 (6.99) | 55 (6.72) | 31 (5.34) | 28 (8.21) | 31 (9.34) | ||
| White | 1604 (77.38) | 620 (75.70) | 445 (76.59) | 269 (78.89) | 270 (81.33) | ||
| Disease characteristics | |||||||
| Duration of disease (months) | 8.53 ± 12.55 | 2.50 ± 2.90 | 2.62 ± 3.00 | 0.48 | 21.94 ± 15.68 | 19.99 ± 15.13 | < 0.001 |
| Duration of disease < 1 year | 1577 (76.07) | 819 (100.00) | 581 (100.00) | – | 86 (25.22) | 91(27.41) | 0.58 |
| RF + , n (%) | 1931 (93.29) | 819 (100.00) | 581 (100.00) | – | 260 (76.47) | 271 (82.12) | < 0.001 |
| ACPA + , n (%) | 1886 (91.07) | 819 (100.00) | 581 (100.00) | – | 250 (73.75) | 236 (71.08) | < 0.001 |
| DAS28 (CRP) Score | 5.71 ± 1.13 | 5.69 ± 1.09 | 5.75 ± 1.08 | 0.29 | 5.68 ± 1.22 | 5.67 ± 1.21 | 0.46 |
| DAS28 (CRP) ≥ 3.2 | 2045 (98.84) | 819 (100.00) | 581 (100.00) | – | 329 (97.34) | 316 (95.47) | 0.27 |
| CRP value (mg/dl) | 2.16 ± 3.10 | 2.21 ± 2.83 | 2.39 ± 3.64 | 0.29 | 1.84 ± 2.44 | 1.96 ± 3.29 | < 0.01 |
| TJC out of 68 joints | 25.11 ± 14.88 | 23.83 ± 14.32 | 24.80 ± 14.01 | 0.21 | 27.20 ± 16.41 | 26.67 ± 15.71 | < 0.001 |
| SJC out of 66 joints | 16.78 ± 10.78 | 15.90 ± 10.37 | 16.59 ± 10.19 | 0.21 | 18.04 ± 12.18 | 17.98 ± 11.03 | < 0.001 |
| HAQ-DI Score | 1.56 ± 0.69 | 1.57 ± 0.68 | 1.58 ± 0.70 | 0.95 | 1.51 ± 0.69 | 1.55 ± 0.68 | 0.17 |
| Patient Global Assessment | 62.95 ± 22.68 | 64.26 ± 22.23 | 62.48 ± 23.28 | 0.15 | 61.95 ± 22.58 | 61.55 ± 22.73 | 0.10 |
| Physician Global Assessment | 63.05 ± 19.23 | 63.72 ± 19.08 | 64.28 ± 19.42 | 0.59 | 61.21 ± 18.27 | 61.12 ± 20.05 | < 0.01 |
| Pain visual analog scale | 65.11 ± 22.06 | 65.16 ± 22.29 | 64.82 ± 21.92 | 0.78 | 64.65 ± 21.96 | 65.96 ± 21.90 | 0.79 |
Data are mean ± SD unless otherwise stated and presented for non-missing data
ABA abatacept, ACPA anti-citrullinated protein antibodies, CI confidence interval, CRP C-reactive protein, DAS28 (CRP) Disease Activity Score 28 for RA with C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, RF rheumatoid factor, SD standard deviation, SJC swollen joint count, SPEAR SeroPositive Early and Active RA, TJC tender joint count